NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Tuesday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.61 on Tuesday. The firm has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.63. The stock has a market capitalization of $3.55 million, a price-to-earnings ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.